Hasan Serdaroglu

Publications (3)7.65 Total impact

• Article: Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination.

  Aynur Baysoy, Hasan Serdaroglu, Hashim Jamal, Emre Karatekeli, Hakan Ozornek, Erkut Attar
  [show abstract] [hide abstract]
  ABSTRACT: This pilot study was conducted to compare the results of intrauterine insemination (IUI) under ovarian stimulation with either letrozole (Femara) or human menopausal gonadotrophin (HMG). A randomized controlled trial was conducted. Eighty women aged 20-35 years with unexplained infertility of at least 2 years' duration were randomized according to a computer-generated randomization list into the letrozole group and the HMG group. Letrozole was administered at 5 mg/day from day 3 to day 7 of the IUI cycle. HMG injections were started on day 3 at a dose of 75 IU for women under 30 years old and 150 IU for women over 30 years old and monitored periodically by vaginal ultrasound and oestradiol concentrations. The variables selected for analysis were clinical pregnancy rate, endometrial thickness, length of follicular phase and number of preovulatory follicles. No statistically significant difference in clinical pregnancy rates per cycle was found for patients in the letrozole or HMG group (18.4 versus 15.7%). Cost was significantly higher in the HMG stimulation cases (P < 0.001) and no injections were required in the letrozole group. In conclusion, letrozole offers a new treatment regimen in ovarian stimulation regimens for IUI that is cost effective, simple and convenient for the patients.
  Reproductive biomedicine online 08/2006; 13(2):208-12. · 2.04 Impact Factor
• Article: Increased concentration of vascular endothelial growth factor in the follicular fluid of patients with endometriosis does not affect the outcome of in vitro fertilization-embryo transfer.

  Erkut Attar, Sema Genc, Sibel Bulgurcuoglu, Samet Topuz, Hasan Serdaroglu
  Fertility and Sterility 01/2004; 80(6):1518-20. · 3.56 Impact Factor
• Article: Effect of leukaemia inhibitory factor on long-term sperm motility and survival.

  Erkut Attar, Bilge Ozsait, Sibel Bulgurcuoglu, Hasan Serdaroglu, Aydin Arici
  [show abstract] [hide abstract]
  ABSTRACT: Leukaemia inhibitory factor (LIF) is expressed at high constitutive levels in the human Fallopian tubal epithelium. In this study, the effect of human recombinant LIF on sperm motility and survival in vitro was investigated. Human spermatozoa were incubated in sperm washing medium that contained various concentrations of LIF at 37 degrees C and under 5% of CO(2) in air for up to 48 h. Sperm motion characteristics were measured using a sperm motility analyser. Sperm survival was determined by the hypo-osmotic swelling test. The effect of LIF on sperm motility was concentration-dependent and maximal effect was observed at a concentration of 5 ng/ml. Sperm motility was significantly higher after 24 h exposure to LIF compared with control (P < 0.001). Sperm survival was also prolonged in a concentration-dependent manner. LIF significantly enhanced sperm survival at higher concentrations (10 ng/ml) and the result was significant after 48 h exposure (P < 0.05). LIF increased long-term sperm motility and survival in vitro.
  Reproductive biomedicine online 7(1):71-4. · 2.04 Impact Factor